Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620000415909
Ethics application status
Approved
Date submitted
12/03/2020
Date registered
27/03/2020
Date last updated
27/03/2020
Date data sharing statement initially provided
27/03/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Testing brain stimulation for improving memory and function in early Alzheimer’s disease.
Query!
Scientific title
Effect of high definition transcranial infraslow pink noise stimulation on cognition and function in individuals with early Alzheimer’s disease: A pilot double-blind randomised controlled study.
Query!
Secondary ID [1]
300777
0
None
Query!
Universal Trial Number (UTN)
U1111-1244-5636
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Early Alzheimer's Disease
316626
0
Query!
Condition category
Condition code
Neurological
314864
314864
0
0
Query!
Alzheimer's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Transcranial electrical stimulation will be administered three times a week (30 minutes/ session) for a total of 8 weeks (i.e. 24 sessions in total) using a 32 channel transcranial current stimulator (Starstim32 TES®, Neuroelectrics, Spain), by a researcher with health professional background and considerable experience in administering non-invasive neuromodulation techniques. The participants will be positioned comfortably and quietly in a seated/half lying position on a bed, and will wear a neoprene head cap with circular stimulation electrodes placed on it. For the active treatment group, the stimulation will be delivered at a current strength of maximum of 2mA for 30min, with 60s ramp up and ramp down at the beginning and end of each stimulation session, with continuous stimulation in between. For sham stimulation, to create an identical skin sensation to the active stimulation, the current will be applied for a 60s ramp up (0-2mA) and 60s ramp down (2-0mA) at the beginning and the end of each stimulation session, without any current for the remainder of the stimulation period.
Query!
Intervention code [1]
317102
0
Treatment: Devices
Query!
Comparator / control treatment
Sham stimulation: To create an identical skin sensation to the active stimulation, the current will be applied for a 60s ramp up (0-2mA) and 60s ramp down (2-0mA) at the beginning and the end of each stimulation session, without any current for the remainder of the stimulation period.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
323203
0
Any adverse events or side effects (e.g. tingling or burning under stimulation electrodes).
The following variables will be recorded:
•Qualitative description of each symptom
•The intensity of each symptom will be measured using a Likert scale ranging from 0 (none) to 10 (extreme)
•Relation of the symptom to the treatment, measured on a scale ranging from 1 (unrelated) to 5 (strongly related).
•Duration of each symptom and the time taken for resolution of each symptom, expressed in minutes.
•Worsening or improvement of symptoms compared to the status prior to the previous session.
•Any drop-outs due to adverse effects will also be recorded.
Query!
Assessment method [1]
323203
0
Query!
Timepoint [1]
323203
0
During each intervention sessions (at intervals of 5 minutes), and immediately post-intervention phase.
Query!
Primary outcome [2]
323204
0
Feasibility measures:
• Recruitment rate, i.e., number of participants per month
• Proportion of participants recruited from the total number screened (with reasons for exclusion) and expressed as a percentage.
• Adherence to intervention measured as number of treatment sessions attended by each participant, and expressed as a percentage of the total number of sessions.
• Drop-out rates, measured as the number of participants who dropped-out in each group, and expressed as a percentage of the total number of participants enrolled in the study.
Query!
Assessment method [2]
323204
0
Query!
Timepoint [2]
323204
0
Throughout the intervention period
Query!
Primary outcome [3]
323205
0
Cognitive tests:
Montreal Cognitive Assessment and Mini- Mental State Examination, and
CANTAB test battery for early AD
• Motor Screening Task
• Reaction Time
• Paired Associates Learning
• Spatial Working Memory
• Pattern Recognition Memory
• Delayed Matching to Sample
• Rapid Visual Information Processing
Query!
Assessment method [3]
323205
0
Query!
Timepoint [3]
323205
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [1]
381173
0
Alzheimer's Disease Functional Assessment and Change Scale
Query!
Assessment method [1]
381173
0
Query!
Timepoint [1]
381173
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [2]
381174
0
European Quality of Life–5 Dimensions
Query!
Assessment method [2]
381174
0
Query!
Timepoint [2]
381174
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [3]
381175
0
Memory Assessment Clinics- family
Query!
Assessment method [3]
381175
0
Query!
Timepoint [3]
381175
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [4]
381176
0
World Health Organisation- Five Well-Being Index
Query!
Assessment method [4]
381176
0
Query!
Timepoint [4]
381176
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [5]
381177
0
State-Trait Anxiety Inventory
Query!
Assessment method [5]
381177
0
Query!
Timepoint [5]
381177
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [6]
381178
0
Intolerance of Uncertainty Scale - Short Form
Query!
Assessment method [6]
381178
0
Query!
Timepoint [6]
381178
0
Baseline and Immediately post-intervention
Query!
Secondary outcome [7]
381179
0
Medical Outcomes Study-Sleep Scale
Query!
Assessment method [7]
381179
0
Query!
Timepoint [7]
381179
0
Baseline and Immediately post-intervention
Query!
Eligibility
Key inclusion criteria
• Capable of understanding and signing an informed consent form
• A diagnosis of ‘probable’ or ‘possible’ Alzheimer’s disease based on National Institute on Aging and Alzheimer’s Association (NIA-AA) guidelines
• A score of 0.5 in the Clinical Dementia Rating scale
• A score of 60 points or higher on the Cambridge Cognitive Examination (CAMCOG-a screening instrument for dementia)
• A score higher than 18 points in the Mini-Mental State Exam (MMSE)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• History of epilepsy or seizures
• History of stroke or tumour
• Unstable medical or psychiatric conditions
• Presence of any pacemaker or defibrillator
• Presence of any metal implant in the body
• Alcohol or substance abuse
• Dyslipidaemia
• History of uncontrolled/untreated hypertension
• Participants who, in the opinion of the investigators, do not understand the information and procedures of the study, or would not be compliant with them.
• Any participant for whom the investigators believe, for any reason, that participation would not be an acceptable risk.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomisation schedule will be concealed in a number sealed and opaque envelopes and provided to the participants at their baseline measurements .
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Descriptive statistics will be used to analyse feasibility and safety measures. Linear mixed model regression analysis will be used to obtain estimates of the intervention effects on cognitive, functional, and quality of life outcome measures.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
4/05/2020
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
29/10/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
24/12/2021
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
22436
0
New Zealand
Query!
State/province [1]
22436
0
Otago
Query!
Funding & Sponsors
Funding source category [1]
305237
0
University
Query!
Name [1]
305237
0
University of Otago Research Grant
Query!
Address [1]
305237
0
PO BOX 56
University of Otago
Dunedin 9054
Query!
Country [1]
305237
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Dr Divya Adhia
Query!
Address
PO BOX 56
University of Otago
Department of Surgical Sciences,
Dunedin School of Medicine.
Dunedin 9054
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
305593
0
None
Query!
Name [1]
305593
0
Query!
Address [1]
305593
0
Query!
Country [1]
305593
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
305580
0
Southern Health and Disability Ethics Committe
Query!
Ethics committee address [1]
305580
0
Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140
Query!
Ethics committee country [1]
305580
0
New Zealand
Query!
Date submitted for ethics approval [1]
305580
0
Query!
Approval date [1]
305580
0
10/03/2020
Query!
Ethics approval number [1]
305580
0
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and to explore the effect of a non-invasive external brain stimulation technique [Transcranial electrical stimulation (TES)] on cognition (e.g. memory, attention), function, and quality of life in individuals with early Alzheimer's disease. The activity in the brain region [posterior cingulate cortex
(PCC)] targeted in the current study have been demonstrated to be altered in the very early stages of AD and are associated with cognitive dysfunctions. The TES technique has considerable potential as a treatment for AD due to its relatively low cost, safety, portability, and ease of use compared with other brain stimulation methods. We propose to explore a novel TES technique [high definition transcranial infraslow pink noise stimulation (HD-tIPNS)] targeting the PCC. The HD-tIPNS technique has been specifically developed in our Otago Brai3n laboratory to modulate the infraslow electrical activity (0.01-0.1 Hz) in the brain. The infraslow electrical activity, a fundamental frequency range of the brain, re-organises neurons, regulate oscillatory patterns in the brain during awake and
sleep cycles, and improves the electrical connectivity of the brain-wide functional networks; thereby improve cognitive functioning. The evidence obtained from this study will thus help us to develop novel interventions to improve the health outcomes (cognition and function) in individuals with early AD.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
100846
0
Dr Divya Adhia
Query!
Address
100846
0
Department of Surgical Science,
Dunedin School of Medicine,
University of Otago.
PO Box 56.
Dunedin 9054, New Zealand
Query!
Country
100846
0
New Zealand
Query!
Phone
100846
0
+64 211167594
Query!
Fax
100846
0
Query!
Email
100846
0
[email protected]
Query!
Contact person for public queries
Name
100847
0
Dr Divya Adhia
Query!
Address
100847
0
Department of Surgical Science,
Dunedin School of Medicine,
University of Otago.
PO Box 56.
Dunedin 9054, New Zealand
Query!
Country
100847
0
New Zealand
Query!
Phone
100847
0
+64 211167594
Query!
Fax
100847
0
Query!
Email
100847
0
[email protected]
Query!
Contact person for scientific queries
Name
100848
0
Dr Divya Adhia
Query!
Address
100848
0
Department of Surgical Science,
Dunedin School of Medicine,
University of Otago.
PO Box 56.
Dunedin 9054, New Zealand
Query!
Country
100848
0
New Zealand
Query!
Phone
100848
0
+64 211167594
Query!
Fax
100848
0
Query!
Email
100848
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF